Tags : Meningococcal


Sanofi Receives the US FDA’s Approval for its MenQuadfi Meningococcal

Shots: The US FDA’s approval is based on five P-II & P-III studies assessing MenQuadfi vs licensed quadrivalent meningococcal in ~5000 people aged ≥2yrs. Four studies evaluated MenQuadfi in meningococcal-naïve person and the other study evaluated MenQuadfi in persons prior to immunized with a quadrivalent meningococcal vaccine Meningococcal-naïve person showed 55.4%–97.2% vaccine induced response 30 […]Read More